en
svPress releases
Regulatory press release 2021-05-06
Xspray Pharma publishes Interim Report Q1, January – March 2021
Regulatory press release 2021-04-20
Notice of annual general meeting of Xspray Pharma AB (publ)
Press release 2021-04-08
Xspray Pharma announces update of its improved version of dasatinib
Regulatory press release 2021-04-08
Xspray Pharma announces the results of two bioequivalence studies with adjusted tablet formulation of HyNap-Dasa (ANDA)
Regulatory press release 2021-03-19
Xspray Pharma publishes its annual report for 2020
Press release 2021-03-18
Xspray Pharma aims to submit its improved version of dasatinib for market approval application in second half of 2021
Press release 2021-03-05
Both groups in the two ongoing bioequivalence studies with Xspray Pharma’s product candidate HyNap-Dasa have been dosed
Regulatory press release 2021-02-25
Xspray Pharma publishes Interim report Q4, January – December 2020
Regulatory press release 2021-02-17
Nomination Committee proposes Anders Ekblom as new Chairman of the Board in Xspray Pharma
Regulatory press release 2021-01-29
Number of shares and votes in Xspray Pharma
Subscribe
IR contact
Christina Malmberg Hägerstrand, SVP Communications & IR